ࡱ>  Root Entry FW#@)FileHeader=DocInfo]|BodyText jFWFW"$%&)(.*+,-'/01234567Root Entry FW@)FileHeader=DocInfo]|BodyText jFWFW !8] <\><Peripheral Cannabinoid 1 Receptor Antagonists: Implications as a drug candidate for the treatment of metabolic disease> <\Դ><The overactivity of cannabinoid 1 receptor (CB1R) is associated with obesity and type 2 diabetes. First-generation CB1R antagonists, such as rimonabant, offered therapeutic advantages for the control of obesity and related metabolic abnormalities, but their therapeutic potential was limited by undesirable neuropsychiatric side effects. We evaluated AJ5012/5018 as a novel potent peripheral CB1R antagonist and, using these antagonists, investigated the role of peripheral CB1R on adipose tissue inflammation and fibrosis in mouse models of obesity. Both antagonists had a high degree of CB1R/CB2R selectivity, but did not elicit centrally mediated neurobehavioral effects. Furthermore, AJ5012/5018 led to a significant reduction in body weight and fat mass, likely owing to an increase in the total energy expenditure. It was as effective as rimonabant for the improvement of ho>lGIF89aɻxxxkkk]]]PPPCCC555((( d`LH00`Hذ̘`H0|pdXL@`0H `H0`dHL`H0xp`XH@0d LȰ``HH00dLؘȀ`H0xp`XH@d0L `H0d`LH`H0|pdXL@0`$H`dHL00`HذȘdL0xp`XH@0` HdH0ȳ``HHdL0xp`XH@`0H Ը̰ĠऀؘpȈXxHp@h@d8`8X0xT0pH dxddxd`d`p`|``x`p``x`!, H*\ȰÇ#JHŋ3jȱǏ CIɓ(S\ɲ˗0cʜI͛8sɳϟ@ JѣH*]ʴӧPJJիXjʵׯ`ÊKYv`ZgoU\mҤ__xK_+^xǐ#KLyaf~x~C{.l75_;ZDڸ6M8v٥wusOuKni﮽yH+<.vk>{߻tp꛻;W_G i܁(rmP&a&VhaIV!\7h^z6o1Lg r 8 v6[g%މ5X]OGtdhat|HZ i6ĤGK6l Wvۙ[:eGaFdޜi{FaxIGk񡖥-Bt:^9w9ib^Lu~fU|BSb4VFZCFeX b6Rf*JjժК5EumE'c:+#{*gi;"b\>ʹEm+Kݖ#'&qA*K*'oFBl5՞%O|eZ[}".ڣ.OG`' g~H0<F6-:*# h.+nq{j v`қz|ofܷR2y*s|Otdjt#JeSh0=Uj=/Aҙ*l0G ɌKߢON"ҝz93׌ߓ,oi/罋j,"7wm'S^| ;M>W9wOo$8Z+z {VZcmQʗ/F:?9T2 neȴ8+tZf9 ֘>}mh3,cJ/?]j׺8Q/HWP Document File\0صɁۡDƹ c(@)^+KlB(]QZh6!ju,X6Ao˘B&<K9:L}3BmKюC gE bW合,#3]u?"X )9C-zo HfLf2S|f.%&ۥKkd1ʵ$ 4Lg*a!w,['Je6-)OgU1vs'o r``yu.]Z6.Α UOcs a]a XQna)HWvS`$ %>6FcKZ@jJABRQiL鲥-HʩkSrv*QMbi۪}GJFg* Mw,,Y=R~$2χ{ Z¡*m^ @ ٫s`.Zy4VF6lǔ*?k1P-?ȩͦӥ^#qQ mh"p#!-nYѲkՎ͏^XN[1="vrjEb{Uj?uo`gTE]lx&JYUcćXl*}v Oip4 \;\|]k|N,K:_]PFT^q[]@v}LƊe*R3R|%qC<aH cd1U=z3ԔhҘ 0ڗ:=+ud1Owİ[諲)R$+@ͥuhVn5E&FeYy?{lzG4{>ɥau_{kmlv7]gW׎ΕvZkz=,P iT]IS;)q2L[qxb==HّVkB/ +xS|Ϲi|(7YYgϻcDm~dWܢw )*^OB7tONuι,';i.tzPuevXݹ%19O?nio#R1ۧ)Wx]W|qu Kxł⥇Iֻ^퍉gOϽwOO;ЏO[ϾO;}{aFׄ_W} zD{`a``a`0x  X d p|ajou2010D 2 10| ”| $ 2:36:28ajou8, 5, 8, 1535 WIN32LEWindows_7@m @FW@yh ^(s5AN ֹ 9VԛNjuTF6A*qWnA=3swlC0AB @""SYQ,!)S !Qnއ7H]sܙ\gދ0&pMQq!vs-n)^;DQhmk m.)apVU |ڪ|a{sLJWQeבcxȴ{Lu\]Rg# \5Vq|󆔒$ϿH_i&FXa;C> +]}ObzA<aɂ芩u)М"itkC }zdEvV^v&P" `!J!D]σi ҕf#/f4MNA1JϫI3-WAV44ˎby%dRxAGT=kڷXsşŠh3n!ME1,ќă^a#h)mFt8օ_3c_Kl^:P Vҵ`#'=aIOcUg͖)Ʃ'nx"ǿ{מDf?vKEv;E[/&aYya|ْYIPg3Վ>ub;rdKyM[ɔdJKszWNݵ Xs]?`u@DO 6C,H,#GB!k0~ 6*7=M*Z:ҙ#?*?ӿT@Y~X+mj3'm[v|:j)%C$Mϼ5#PUG\=m`@hH_)e%I?r-ȗsR8e%A𱪦cd߈QiQU/״ퟟ?/!YyfgZrthermore, AJ5012 did not V=lU]9bB !lQ2 $+ [eG{w&)ҧ@B!(\P A&e *JE" |(wz;yN#$9<,Kvn6 6_:~>_7v?i: jZVt|FfTwyN- Z}!ۨ9oʋ2| ՛nok=oY~H2Tõǒst' !"#$%&'()*+,-./0123456789:;<A>?@BCDEFGHIJKLMNOPQRSTVWXYZ[\^_`abcdefghijklmnpqtuvwxyz{}~HwpSummaryInformation.UPrvImage  PrvTextDocOptions FWFWSection0|) QU52uܨ(G*wgtl."#(ٲω^1ҿyKW*js#$ yh=uf1r-fW?>Ʈܻ屫$͍< -_n-P4Ԋ:f}H:r,PТSU )944+:ԡ(ԥ&.%,d5y5clP"]4b^}{w]y.D;`YH{|Ů <c^1*k614y[F`2c1 =shtDTGB;Y>8ԛ+̹u^"kʑ}+!4aƲ8q1e `Yיy#$eyN{WbORG-h=}oр֚xهU^]+jUў، W%2kJ £DYd]%1u^24D@'<>T{$Bm+1vym8+ zV >n`'F>Bktޡ79˴dVJm"zALI3XcTv` ?3L< qlP売CUHt!jXm5-0"U `;6b]7{s8SX*Zͩ(gAI؝ǞFeÃ`Gy]7} O\9 -0&HFl 9(x<f) = Z 4FY;hV s*OM̚9O 9AUˤW齋n;]7gsxnw]EC6v KVOh ڌǐ Qu⋤gj|i1Mk^cZ- <}z徾XJo>, ۦrN btQ ^3lZ#bIV)(BEH&I\5h@ bHJ|,AU"! fEDV{gw7s])8ý{ι==MIIAiΡÒ~}RxnϒHz0ڍf7ihsL8ʱ aIML-1B 9%'{RHR fxo!bR>ʱ汄.I4ͽ;sڲ*`BO.Pwxv]>!|MxMb@jw4Gܸ).#n| =Occph`f& fbpI`cdpdP`bۃA bHe(D"d H .< `8ؕd0 f&-'A$%| ]r #U`(8V>C^ݾU; rh9LyX-Vh=Ft~Bo٣P_~,PяyLww_1C=Ek=CU^eIdXN_^FF ]ܖʂ5EtuQa6o9y^^U3j!/VPu5T8n V_JG=C*]}728H"o_܍̷ʊ{HwpSummaryInformation.UPrvImage  PrvTextDocOptions FWFWScripts FW FWJScriptVersion r DefaultJScripto_LinkDocs Section0|)  !"#$%&'()*+,-./0123456789:;<A>?@BCDEFGHIJKLMNOPQRSTVWXYZ[\^_`abcdefghijklmnpqtuvwxyz{}~